Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02257424
Title Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma (BAMM)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

melanoma

Therapies

Dabrafenib + Hydroxychloroquine + Trametinib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST